Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Kohn
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Orchard Therapeutics
Reimbursed or sponsored travel
Dr. Kohn serves on the Scientific Advisory Board of Orchard Therapeutics, a biotechnology company that aims to develop gene therapies and is providing the funding for the vector production in this trial. The trial is an investigator-initiated, multi-institutional trial with an independent DSMB and independent monitor consultant. The trial was designed and developed by the multi-investigator team with no representation from Orchard. Because of his expertise in the area, Dr. Kohn acts as a paid consultant and provides advice and guidance to the Company.
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector
Project Narrative Severe combined immunodeficiency (SCID) is a fatal genetic disorder in which babies are born missing T lymphocytes, a key component of the immune system. Now that more than 75% of babies are screened at birth through universal newborn screening for SCID, we have the chance to identify and treat SCID before death from infection. This study will test whether gene therapy can safely and effectively treat the X-linked form of SCID, SCID-X1.
Filed on April 23, 2018.
Tell us what you know about Donald Kohn's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Donald Kohn”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Donald Kohn | Boston Children's Hospital | Conflict of Interest | Orchard Therapeutics | $150,000 - $199,999 |
| Donald Kohn | University of California Los Angeles | Conflict of Interest | Orchard Therapeutics | Value cannot be readily determined |
| Donald Kohn | University of California Los Angeles | Conflict of Interest | Orchard Therapeutics | Value cannot be readily determined |
| Donald Kohn | University of California Los Angeles | Conflict of Interest | Orchard Therapeutics | Value cannot be readily determined |
| Donald Kohn | University of California Los Angeles | Conflict of Interest | Orchard Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.